ANNOUNCEMENT

Check out the MedCity CONVERGE speaker lineup: Pfizer, Cleveland Clinic, Intel and more.

Hirschler, Ben

Follow Hirschler, Ben: Website |


Investor-backed thinktank calls for changes to drug funding and approval

Investor-backed thinktank calls for changes to drug funding and approval

June 18, 2013 7:02 pm by | 0 Comments

LONDON (Reuters) - Pharmaceutical companies need to boost the benefits of drug research by working with regulators and healthcare providers to overhaul the way medicines are approved and paid for, ... Read more

No short-term fixes for AstraZeneca, turnaround will take 3 to 4 years

No short-term fixes for AstraZeneca, turnaround will take 3 to 4 years

June 18, 2013 12:20 pm by | 0 Comments

LONDON (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay ... Read more


GSK in discussions to sell thrombosis drugs to Aspen in $1B deal

GSK in discussions to sell thrombosis drugs to Aspen in $1B deal

June 18, 2013 9:03 am by | 0 Comments

LONDON (Reuters) - GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could ... Read more

Sanofi’s “painful” MS drug development saga may be ending

Sanofi’s “painful” MS drug development saga may be ending

June 10, 2013 7:45 am by | 0 Comments

LONDON (Reuters) - One of the world's longest running drug development sagas may draw to a close this month as French firm Sanofi hopes for a European green light for ... Read more

Genomics is hot and so are the researchers uncovering its secrets

Genomics is hot and so are the researchers uncovering its secrets

June 5, 2013 1:08 am by | 0 Comments

LONDON (Reuters) - Genomics and particle physics - offering different perspectives on the fundamental nature of life and the cosmos - are the two hottest areas of scientific research.Eight of ... Read more

AstraZeneca’s new-drug pipeline takes hit, bigger setback for partner Rigel

AstraZeneca’s new-drug pipeline takes hit, bigger setback for partner Rigel

June 4, 2013 2:15 am by | 0 Comments

LONDON (Reuters) - AstraZeneca has decided to end development of fostamatinib, a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing overall results.The decision is ... Read more

AstraZeneca builds up cardiovascular drug business with Omthera acquisition

AstraZeneca builds up cardiovascular drug business with Omthera acquisition

May 28, 2013 2:20 am by | 0 Comments

LONDON (Reuters) - AstraZeneca is to buy Omthera Pharmaceuticals for as much as $443 million to build up its cardiovascular drug business, a priority area for Britain's second-biggest drugmaker.The acquisition ... Read more


AstraZeneca needs new new products as others lose patent protection, accelerates drug pipeline

AstraZeneca needs new new products as others lose patent protection, accelerates drug pipeline

May 16, 2013 6:10 am by | 0 Comments

LONDON (Reuters) - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group's new CEO delivers ... Read more

Big drugmakers think small with nanomedicine deals

Big drugmakers think small with nanomedicine deals

May 3, 2013 6:03 am by | 0 Comments

LONDON (Reuters) - Is nanomedicine the next big thing? A growing number of top drug companies seem to think so.The ability to encapsulate potent drugs in tiny particles measuring billionths ... Read more

Court stops EU regulator from releasing drug company data

Court stops EU regulator from releasing drug company data

April 30, 2013 8:30 am by | 0 Comments

LONDON (Reuters) - Europe's medicines regulator has been stopped from releasing clinical trial data about drugs made by AbbVie and Intermune, following a court ruling favoring the two U.S. companies.The ... Read more

Big brain projects highlight drug research gaps

Big brain projects highlight drug research gaps

April 11, 2013 7:25 am by | 0 Comments

LONDON (Reuters) - Governments on both sides of the Atlantic are placing big new bets on the future of brain science, just as much of the pharmaceutical industry retreats from ... Read more

Big Pharma down, not out, after Indian patent blow

Big Pharma down, not out, after Indian patent blow

April 2, 2013 10:53 am by | 0 Comments

LONDON/MUMBAI (Reuters) - Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country tipped to ... Read more

New vaccine for foot-and-mouth disease made totally from synthetic protein

New vaccine for foot-and-mouth disease made totally from synthetic protein

March 27, 2013 6:03 pm by | 0 Comments

LONDON (Reuters) - British scientists have developed a new vaccine against foot-and-mouth disease that is safer and easier to manufacture, an advance they believe should greatly increase production capacity and ... Read more

Experts: European financial crisis has direct impact on healthcare

Experts: European financial crisis has direct impact on healthcare

March 26, 2013 8:09 pm by | 1 Comments

LONDON (Reuters) - Europe's financial crisis is costing lives, with suicides and infectious diseases on the rise, yet politicians are not addressing the problem, health experts said on Wednesday. Deep ... Read more

GlaxoSmithKline boss says new drugs can be cheaper

GlaxoSmithKline boss says new drugs can be cheaper

March 14, 2013 11:15 am by | 0 Comments

LONDON (Reuters) - The pharmaceutical industry should be able to charge less for new drugs in future by passing on efficiencies in research and development to its customers, according to ... Read more